From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
5′-Nucleotidase, Microorganism (CD73) is an intrinsic membrane glycoprotein present as an ectoenzyme. 5′-Nucleotidase catalyzes hydrolysis of 5-nucleotides to their corresponding nucleosides .
CD73-IN-4 is a potent and selective methylenephosphonic acid CD73 inhibitor, with an IC50 of 2.6 nM for human CD73. CD73-IN-4 is potential for the research of cancer immunology .
Nt5e Rat Pre-designed siRNA Set A contains three designed siRNAs for Nt5e gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Nt5e Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nt5e gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
NT5E Human Pre-designed siRNA Set A contains three designed siRNAs for NT5E gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
CD73-IN-13 is a potent inhibitor of CD73. CD73 is closely associated with tumor growth, angiogenesis and metastasis. CD73-IN-13 be used for preparing a medicament for tumor-related diseases (extracted from patent CN114437039A, compound 7) .
CD73-IN-12 is a potent inhibitor of CD73. CD73 is closely associated with tumor growth, angiogenesis and metastasis. CD73-IN-12 be used for preparing a medicament for tumor-related diseases (extracted from patent CN114437038A, compound 9) . CD73-IN-12 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
CD73-IN-19 (Compound 4ab) is a CD73 inhibitor (with a 44% inhibition rate of CD73 enzymatic activity at 100 μM). CD73-IN-19 (at 10 μM and 100 μM) can completely antagonize the blockade of T cell proliferation induced by TCR (T cell receptor) triggering (which is induced by CD73 activity), and it can also inhibit the hA2A receptor activity in HEK-293 cells (Ki is 3.31 μM). CD73-IN-19 holds promise for research in the field of immune diseases .
CD73-IN-3 is a potent CD73 inhibitor (IC50=7.3 nM in Calu6 human cell assay). CD73-IN-3, example 2 extracted from patent WO2019168744 A1, has the potential for cancer research .
CD73-IN-11 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-11 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 24) .
CD73-IN-10 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-10 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 4) .
CD73-IN-8 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-8 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022052886A1, compound 57) .
CD73-IN-9 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-9 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 2) .
CD73-IN-7 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-7 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022052886A1, compound 13) .
D73-IN-14 is a potent, selective and orally active CD73 inhibitor with an IC50 value of 0.17 nM. CD73-IN-14 increases the number of tumor-infiltrating CD8 + cells and shows anti-tumor activity . CD73-IN-14 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
PD-L1/CD-73-IN-1 (compound CC-5) is PD-L1/CD73 inhibitor with IC50 values of 6 nM and 0.773 μM to PD-L1 and CD73, respectively. PD-L1/CD-73-IN-1 inhibits tumor cell growth in vivo and in vitro .
PSB-24000 (Compound 27) is a selective ecto-5'-nucleotidase (CD73) inhibitor with a Ki value of 563 nM against human CD73 (Ki= 481 nM at membrane-bound CD73 in triple-negative breast cancer cells). PSB-24000 interferes with CD73's recognition and action on the substrate AMP, and prevents the generation of immunosuppressive and cancer-promoting adenosine from AMP. PSB-24000 is promising for research of cancers .
ST80 is an inhibitor for interaction of OTUD4 and CD73. ST80 decreases CD73 protein level, increases CD73 protein turnover, reduces immune evasion of tumor cells, and thus exhibits antitumor efficacy against immunosuppressive triple-negative breast cancer (TNBC) .
XC-12 is an orally active and potent small-molecule CD73 inhibitor (an immune checkpoint) with IC50 values of 12.36 nM and 1.29 nM against soluble and membrane-bound CD73 forms, respectively. XC-12 is promising for research of cancers .
8-BuS-AMP is a CD39 and CD73 dual inhibitor. 8-BuS-AMP inhibits human CD39, mouse CD39 and human CD73 with Kis of 0.292, 2.19 and 1.19 μM, respectively .
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity .
BMS-986179 is a human monoclonal antibody (mAb) targeting NT5E/CD73. BMS-986179 inhibits CD73 enzymatic activity in tumor vasculature and tumor cells. BMS-986179 can be used in advanced solid tumors research .
MethADP (Adenosine 5'-(α,β-methylene)diphosphate) trisodium is a CD73 inhibitor. MethADP trisodium can be used for the research of ATP-adenosine pathway .
IPH5301 is a human IgG1 monoclonal antibody (mAb) targeting NT5E/CD73. IPH5301 has a functionally silent Fc domain, specifically inhibits soluble and membrane CD73 enzyme activity, and restores the proliferation of immune T cells. IPH5301 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer .
OP-5244 is a potent and orally active inhibitor of CD73, with an IC50 of 0.25 nM. OP-5244 reverses immunosuppression through blocking of adenosine production, and has the potential for the cancer research .
OP-5244 sodium is a potent and orally active inhibitor of CD73, with an IC50 of 0.25 nM. OP-5244 sodium reverses immunosuppression through blocking of adenosine production, and has the potential for the cancer research .
ZM514 is a potent CD73 inhibitor with IC50s of 1.39 μM and 14.65 μM for hCD73 and mCD73, respectively. ZM514 has low cytotoxicity. ZM514 can be used for researching anticancer .
JAB-BX102 is a human monoclonal antibody (mAb) targeting NT5E/CD73. JAB-BX102 can be used in the study of cancers such as breast cancer, pancreatic cancer, and prostate cancer .
AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity .
ORIC-533 is an orally active, selective CD73 inhibitor with AMP-competition. ORIC-533 restores immunosuppressed CD8+ T cell proliferation and activation, triggers significant lysis and cell death of multiple myeloma cells in the bone marrow microenvironment .
AB-680 ammonium is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity .
ZM522 is a CD73 inhibitor with an IC50 value of 0.56 μM. ZM522 effectively increases the levels of interferon-γ (INF-γ) and enhances immune activity by regulating the activation status of T cells. ZM522 holds promise for research in the fields of immunology and cancer therapy .
BK50164 is a potent CD73 inhibitor with an IC50 value of 13.089 µM. BK50164 binds to CD99 with a KD value of 1.5 µM. BK50164 shows antiproliferative activity. BK50164 induced Apoptosis and cell cycle arrest at Sub-G1 phase .
ARL67156 (FPL 67156) trisodium is a selective small molecular inhibitor, targeting to ecto-ATPase, CD39, and CD73. ARL67156 trisodium is also a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with Kis of 11, 18 and 12?μM, respectively. ARL67156 trisodium can be used in the research of calcific aortic valve disease, asthma .
ARL67156 (FPL 67156) trisodium hydrate is a selective small is a selective samll molecular inhibitor, targeting to ecto-ATPase, CD39, and CD73. ARL67156 trisodium hydrate is also a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with Kis of 11, 18 and 12 μM, respectively. ARL67156 trisodium hydrate can be used in the research of disease like calcific aortic valve disease, asthma .
ARL67156 (FPL 67156) triethylamine is a selective small is a selective samll molecular inhibitor, targeting to ecto-ATPase, CD39, and CD73. ARL67156 triethylamine is also a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with Kis of 11, 18 and 12 μM, respectively. ARL67156 triethylamine can be used in the research of disease like calcific aortic valve disease, asthma .
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity .
Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer .
BMS-986179 is a human monoclonal antibody (mAb) targeting NT5E/CD73. BMS-986179 inhibits CD73 enzymatic activity in tumor vasculature and tumor cells. BMS-986179 can be used in advanced solid tumors research .
IPH5301 is a human IgG1 monoclonal antibody (mAb) targeting NT5E/CD73. IPH5301 has a functionally silent Fc domain, specifically inhibits soluble and membrane CD73 enzyme activity, and restores the proliferation of immune T cells. IPH5301 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
JAB-BX102 is a human monoclonal antibody (mAb) targeting NT5E/CD73. JAB-BX102 can be used in the study of cancers such as breast cancer, pancreatic cancer, and prostate cancer .
CD73/5'-Nucleotidase Protein Protein, Mouse (HEK293, His) is a recombinant mouse CD73 expressed by HEK293 cells with His tag. CD73 is a cell surface enzyme that catalyzes the dephosphorylation of extracellular AMP to adenosine.
CD73/5'-Nucleotidase Protein, Cynomolgus (HEK 293, His) is a CD73 protein with a His-flag. CD73/5'-Nucleotidase Protein a zinc-dependent, 70 kDa homodimeric enzyme that binds to the cell membrane through a glycosyl phophatidylinositol (GPI) anchor.
CD73/5'-Nucleotidase Protein hydrolyzes nucleotide monophosphates, favoring AMP as the primary substrate and showing a preference for ribonucleotide monophosphates. It releases inorganic phosphate and the corresponding nucleoside. CD73 also acts on other substrates, including IMP, UMP, GMP, CMP, dAMP, dCMP, dTMP, NAD, and NMN. CD73/5'-Nucleotidase Protein, Human (HEK293, His) is the recombinant human-derived CD73/5'-Nucleotidase protein, expressed by HEK293 , with C-6*His labeled tag.
CD73/5'-Nucleotidase Protein hydrolyzes nucleotide monophosphates, favoring AMP as the primary substrate and showing a preference for ribonucleotide monophosphates. It releases inorganic phosphate and the corresponding nucleoside. CD73 also acts on other substrates, including IMP, UMP, GMP, CMP, dAMP, dCMP, dTMP, NAD, and NMN. CD73/5'-Nucleotidase Protein, Human (T376A, M379T, HEK293, His) is the recombinant human-derived CD73/5'-Nucleotidase protein, expressed by HEK293 , with C-6*His labeled tag.
CD73/5'-Nucleotidase Protein, Rat (HEK293, His) is a 70-90 kDa rat CD73 protein with His-flag expressed by HEK293. Rat CD73 is a cell membrane protein that catalyzes the conversion of purine and pyrimidine ribo- and deoxyribonucleoside monophosphates to the corresponding nucleosides.
CD73/5'-Nucleotidase Protein hydrolyzes nucleotide monophosphates, favoring AMP as the primary substrate and showing a preference for ribonucleotide monophosphates. It releases inorganic phosphate and the corresponding nucleoside. CD73 also acts on other substrates, including IMP, UMP, GMP, CMP, dAMP, dCMP, dTMP, NAD, and NMN. CD73/5'-Nucleotidase Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived CD73/5'-Nucleotidase protein, expressed by HEK293 , with C-His labeled tag.
CD73/5'-Nucleotidase Protein hydrolyzes nucleotide monophosphates, favoring AMP as the primary substrate and showing a preference for ribonucleotide monophosphates. It releases inorganic phosphate and the corresponding nucleoside. CD73 also acts on other substrates, including IMP, UMP, GMP, CMP, dAMP, dCMP, dTMP, NAD, and NMN. CD73/5'-Nucleotidase Protein, Human (T376A, HEK293, Fc) is the recombinant human-derived CD73/5'-Nucleotidase protein, expressed by HEK293 , with C-hFc labeled tag.
CD73/5'-Nucleotidase Protein hydrolyzes nucleotide monophosphates, favoring AMP as the primary substrate and showing a preference for ribonucleotide monophosphates. It releases inorganic phosphate and the corresponding nucleoside. CD73 also acts on other substrates, including IMP, UMP, GMP, CMP, dAMP, dCMP, dTMP, NAD, and NMN. CD73/5'-Nucleotidase Protein, Rabbit (HEK293, His) is the recombinant Rabbit-derived CD73/5'-Nucleotidase protein, expressed by HEK293 , with C-His labeled tag. The total length of CD73/5'-Nucleotidase Protein, Rabbit (HEK293, His) is 524 a.a., with molecular weight of 60-65 kDa.
CD73/5'-Nucleotidase Protein hydrolyzes nucleotide monophosphates, favoring AMP as the primary substrate and showing a preference for ribonucleotide monophosphates. It releases inorganic phosphate and the corresponding nucleoside. CD73 also acts on other substrates, including IMP, UMP, GMP, CMP, dAMP, dCMP, dTMP, NAD, and NMN. CD73/5'-Nucleotidase Protein, Canine (HEK293, His) is the recombinant canine-derived CD73/5'-Nucleotidase protein, expressed by HEK293 , with C-His labeled tag. The total length of CD73/5'-Nucleotidase Protein, Canine (HEK293, His) is 523 a.a., with molecular weight of ~65 kDa.
CD73/5'-Nucleotidase Protein hydrolyzes nucleotide monophosphates, favoring AMP as the primary substrate and showing a preference for ribonucleotide monophosphates. It releases inorganic phosphate and the corresponding nucleoside. CD73 also acts on other substrates, including IMP, UMP, GMP, CMP, dAMP, dCMP, dTMP, NAD, and NMN. CD73/5'-Nucleotidase Protein, Sus scrofa (HEK293, His) is the recombinant CD73/5'-Nucleotidase protein, expressed by HEK293 , with C-His labeled tag. The total length of CD73/5'-Nucleotidase Protein, Sus scrofa (HEK293, His) is 523 a.a., with molecular weight of 60-65 kDa.
CD73 Antibody (YA528) is a non-conjugated and Rabbit origined monoclonal antibody about 63 kDa, targeting to CD73. It can be used for WB,IHC-P assays with tag free, in the background of Human.
CD73 Antibody (YA797) is a non-conjugated and Mouse origined monoclonal antibody about 63 kDa, targeting to CD73. It can be used for WB,IHC-P,IF,FC assays with tag free, in the background of Human.
CD73 is a 70 kD glycophosphatidylinositol (GPI)-linked 5'-nucleotidase, which is also known as ecto-5'-nucleotidase. It converts adenosine monophosphate (AMP) to adenosine. CD73 is expressed on subsets of T and B cells, mesenchymal stem cells, follicular dendritic cells, endothelial cells, and epithelial cells. It has been reported that CD73 costimulates T cell activation, and mediates adhesion of lymphocytes to follicular dendritic cells and endothelial cells.
D73-IN-14 is a potent, selective and orally active CD73 inhibitor with an IC50 value of 0.17 nM. CD73-IN-14 increases the number of tumor-infiltrating CD8 + cells and shows anti-tumor activity . CD73-IN-14 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Nt5e Rat Pre-designed siRNA Set A contains three designed siRNAs for Nt5e gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Nt5e Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nt5e gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
NT5E Human Pre-designed siRNA Set A contains three designed siRNAs for NT5E gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
